Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
According to schedule, 2cureX’s clinical partner University Hospital Vejle has treated the last patient in the TICC1 clinical trial (Clinicaltrials.gov no. NCT03251612) in metastatic colorectal cancer.2cureX and University Hospital Vejle are in the process of analyzing the clinical data from the trial with expected publication of the results in first quarter of 2021.2cureX will provide update of the clinical study at Redeye’s Fight Cancer 2021 Seminar on 21. January (Fight Cancer 2021 – Jan 21st - Redeye.se ). For more information